Atherosclerosis Therapeutics

Global Atherosclerosis Therapeutics Market to Reach US$13.7 Billion by 2030

The global market for Atherosclerosis Therapeutics estimated at US$11.1 Billion in the year 2024, is expected to reach US$13.7 Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2024-2030. Atherosclerosis Small Molecules, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$9.2 Billion by the end of the analysis period. Growth in the Atherosclerosis Biologics segment is estimated at 2.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 6.7% CAGR

The Atherosclerosis Therapeutics market in the U.S. is estimated at US$3.0 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 6.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Atherosclerosis Therapeutics Market – Key Trends & Drivers Summarized

Why Is Atherosclerosis Still a Global Health Crisis Despite Medical Advances?

Atherosclerosis, characterized by the progressive buildup of plaque in arterial walls, remains one of the leading contributors to cardiovascular diseases worldwide. Despite decades of research and the availability of effective therapeutic interventions, it continues to claim millions of lives annually due to heart attacks, strokes, and peripheral arterial disease. This persistent prevalence is partly due to lifestyle factors such as unhealthy diets, sedentary behavior, smoking, and increasing stress levels that collectively elevate the risk of plaque formation. Furthermore, atherosclerosis often develops silently over decades before manifesting in acute cardiovascular events, which makes early detection and intervention particularly challenging. Populations in both high-income and developing countries are increasingly affected as globalization introduces western dietary habits and urbanization contributes to reduced physical activity. Compounding this issue is the rise in coexisting conditions such as diabetes, hypertension, and obesity, all of which are significant accelerators of atherosclerotic progression. Moreover, demographic shifts, especially the global increase in aging populations, have resulted in a growing patient base at risk of or already suffering from atherosclerosis-related complications. Although statins and other lipid-lowering agents have proven effective in managing cholesterol levels, they are often underutilized or insufficient for certain high-risk populations. Patient adherence, limited access to healthcare, and asymptomatic progression also hinder effective disease control. These multifaceted challenges emphasize why atherosclerosis remains an urgent global health concern and highlight the need for more sophisticated, accessible, and personalized therapeutic approaches.

How Is Innovation Reshaping the Landscape of Atherosclerosis Treatment?

The therapeutic landscape for atherosclerosis is undergoing significant transformation, fueled by advancements in biotechnology, precision medicine, and molecular research. Traditional therapies, such as statins and antiplatelet drugs, continue to form the cornerstone of treatment; however, new approaches are emerging that go beyond lipid management to address the underlying inflammatory and immune pathways driving plaque buildup. Monoclonal antibodies, such as PCSK9 inhibitors, have introduced a new era of lipid-lowering therapies that can achieve cholesterol reductions previously unattainable through conventional drugs. These biologics are particularly useful for patients with familial hypercholesterolemia or those who are statin-intolerant. Gene-editing technologies, including CRISPR, are also being explored to modify genes associated with lipid metabolism, potentially offering long-term protection against atherosclerosis. Another area of growth is RNA-based therapeutics, which can silence specific genetic targets involved in lipid synthesis or inflammation. Imaging technologies, such as intravascular ultrasound and optical coherence tomography, are now being integrated with treatment strategies to monitor plaque characteristics and assess therapeutic responses in real time. Drug-eluting stents and vascular scaffolds have evolved in both safety and efficacy, providing localized therapy that complements systemic medication. Additionally, the use of digital health tools and wearable devices is allowing for continuous cardiovascular monitoring and personalized treatment adjustments. Collectively, these innovations are not only improving outcomes for high-risk patients but also redefining how atherosclerosis is diagnosed, monitored, and managed across its entire clinical continuum.

What External Forces Are Steering the Direction of Therapeutic Development?

Beyond the scientific advancements, external factors such as healthcare policy, regulatory frameworks, economic disparities, and public awareness campaigns are playing pivotal roles in shaping the atherosclerosis therapeutics market. Government-led initiatives aimed at reducing the global burden of cardiovascular disease are resulting in broader screening programs and funding for preventive therapies, particularly in regions experiencing rapid urbanization and lifestyle shifts. Regulatory bodies are beginning to fast-track approvals for breakthrough therapies addressing high-risk atherosclerosis patients who fail to respond to standard treatments. At the same time, pharmaceutical companies are investing more aggressively in developing novel compounds, driven by the high market potential and unmet clinical needs. Health systems are increasingly favoring value-based care models, which incentivize early intervention and long-term disease management over episodic treatment. These models promote the adoption of therapeutics that not only lower cholesterol but also demonstrate reductions in cardiovascular events and mortality. Furthermore, socioeconomic disparities continue to influence treatment accessibility, with many low- and middle-income populations struggling to afford advanced therapies or maintain consistent follow-up care. This has led to increased interest in developing cost-effective generic formulations and long-acting drugs that reduce the burden of daily medication adherence. Public education and awareness campaigns are also improving patient understanding of atherosclerosis and encouraging earlier consultations, thereby supporting demand for diagnostic and therapeutic solutions. The interplay of these regulatory, economic, and societal factors is instrumental in directing the pace and focus of innovation within the atherosclerosis therapeutics sector.

What Factors Are Driving Growth in the Atherosclerosis Therapeutics Market?

The growth in the atherosclerosis therapeutics market is driven by several factors rooted in demographic trends, scientific advancement, and evolving healthcare delivery models. One of the most significant drivers is the aging global population, which presents a higher prevalence of cardiovascular risk factors, thereby increasing the demand for long-term atherosclerosis management. Simultaneously, the rising incidence of lifestyle-related conditions such as obesity, type 2 diabetes, and metabolic syndrome is expanding the pool of patients requiring treatment for atherosclerosis or its associated complications. Advances in pharmacogenomics and precision medicine are enabling more targeted therapeutic interventions, boosting efficacy and reducing adverse effects. In addition, healthcare providers are increasingly integrating digital tools that support remote monitoring and treatment adherence, thus expanding the market for supportive therapeutics that complement traditional medications. The entry of novel drug classes, including PCSK9 inhibitors, CETP inhibitors, and anti-inflammatory agents, is further enhancing therapeutic options, especially for patients resistant to first-line treatments. Payers and insurers are beginning to recognize the cost-effectiveness of early and aggressive treatment in reducing long-term healthcare expenditures, leading to more favorable reimbursement policies for advanced therapies. Furthermore, ongoing clinical trials and regulatory approvals are introducing new pipeline candidates into the market at a steady pace, keeping innovation momentum high. The shift toward holistic cardiovascular care, encompassing lifestyle management, diagnostics, and pharmaceutical intervention, is reinforcing the demand for multi-modal therapeutic approaches. As a result, the market for atherosclerosis therapeutics is not only expanding in volume but also diversifying in scope, driven by a combination of clinical need, technological evolution, and strategic healthcare planning.

SCOPE OF STUDY:

The report analyzes the Atherosclerosis Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Atherosclerosis Small Molecules, Atherosclerosis Biologics)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• Bristol-Myers Squibb
• Daiichi Sankyo Co., Ltd.
• Eli Lilly and Company
• GlaxoSmithKline plc (GSK)
• Ionis Pharmaceuticals, Inc.
• Kowa Company, Ltd.
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Regeneron Pharmaceuticals
• Roche Holding AG
• Sanofi S.A.
• Takeda Pharmaceutical Co.
• Teijin Pharma Limited
• Zai Lab Limited

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more